Service Hotline +86 400-068-7188
Service Hotline +86 400-068-7188
China Massive Health Industry Report (2016-2021), Market Outlook and Investment Opportunity
A must-have for enterprise medium to long-term strategic planning
Without deep industry knowledge, it will be difficult to gain any return
English Version：USD7900
Including: Paper back + Electronic Copy + Invoice
Customer Hotline：+86 755 - 82925195 / 82925295
Free Hotline：+86 400-068-7188After-sales Hotline： +86 755-33013088
The Ministry of Commerce of the People's Republic of China designated Qianzhan Industrial Research Institute as the only "regional workstation for dealing with trade friction" in the Guangdong-Hong Kong-Macao Greater Bay Area
Customer Hotline：+86 755 - 82925195 / 82925295
Free Hotline：+86 400-068-7188
0755 - 82925195
400-068-7188
We are aware of that the content of our products have been stolen by some ones who changed the design and used it to deceive customers as it is their own products. Customers who are misled may experience no product received or an incomplete product.
Therefore, Qianzhan Industrial Research Institute encourage you to arrange an in-person visit to our company before you make the purchase.
Qianzhan has the sole copyright of all research reports. We have never had partnership or affiliated with any third party agent. Please recognize the"
"trademark when purchasing reports.To have better investment return or strategic outcomes, you must have a forward-looking vision. Qianzhan Industrial Research Institute - China's leading industry consulting institutions provide you with all the things you need in business!
* The table of contents and the rest of this report are originally created by Qianzhan. Without any prior written permission, it is prohibited to copy or reproduce in any way. To have better investment return or strategic outcomes, you must have a forward-looking vision!
Table of Contents
Content Summary
Chapter 1: Background of development of China's massive health industry
1.1 scope of research of massive health industry
1.1.1 scope of massive health
1.1.2 scope of massive health industry
1.1.3 scope of massive health strategy
1.2 analysis of development environment of China's massive health industry
1.2.1 policy environment of massive health industry
1.2.2 economic environment of massive health industry
1.2.3 social environment of massive health industry
1.3 analysis of comprehensive benefits of massive health strategy
1.3.1 analysis of economic benefit of massive health industry
1.3.2 analysis of social benefit of massive health industry
1.3.3 analysis of marketing benefit of massive health industry
Chapter 2: Analysis of China's pharmaceutical companies into massive health industry
2.1 policy environment for pharmaceutical companies into massive health
2.1.1 interpretation of national supportive policies and regulations
2.1.2 government's positioning towards massive health
2.1.3 Forward's prediction of massive health policy for future years
2.2 status quo of pharmaceutical companies into massive health industry
2.2.1 overview of China's pharmaceutical companies to enter massive health
2.2.2 advantages of China's pharmaceutical companies to enter massive health
2.2.3 analysis of China's pharmaceutical companies that have entered massive health
2.2.4 analysis of scale of massive health market of China's pharmaceutical companies
2.2.5 analysis of profit of China's pharmaceutical companies to enter massive health
2.2.6 product distribution of China's pharmaceutical companies to enter massive health
2.2.7 channel selection of China's pharmaceutical companies to enter massive health
2.3 channel strategy of pharmaceutical companies into massive health
2.3.1 analysis of drugstore chain channel
(1) analysis of advantages and disadvantages of drugstore chain channel
(2) cases and the effectiveness of drugstore chain channel
(3) reference of experience of selection of drugstore chain channel
(4) analysis of feasibility of selection of drugstore chain channel
2.3.2 analysis of traditional supermarket channel
(1) entry barriers of traditional supermarket channel
(2) degree of monopoly of traditional supermarket channel
(3) analysis of advantages and disadvantages of traditional supermarket channel
(4) cases and the effectiveness of traditional supermarket channel
(5) reference of experience of selection of traditional supermarket channel
(6) analysis of feasibility of selection of traditional supermarket channel
2.3.3 analysis of emerging e-commerce channel
(1) development pace of emerging e-commerce channel
(2) analysis of advantages and disadvantages of emerging e-commerce channel
(3) points of selection of emerging e-commerce channel
(4) analysis of feasibility of selection of emerging e-commerce channel
2.4 reference of experience of case of pharmaceutical companies to enter massive health industry
2.4.1 reference of experience of success stories of Yunnan Baoyao
2.4.2 reference of experience of success stories of Wong Lo Kat
2.5 ideas on pharmaceutical companies to enter massive health industry and forecast
2.5.1 analysis of ideas on pharmaceutical companies to enter massive health industry
(1) analysis of ideas on product selection
(2) analysis of ideas on product positioning
(3) analysis of ideas on channel selection
(4) analysis of ideas on brand marketing
(5) analysis of ideas on marketing
(6) analysis of ideas on market competition
2.5.2 Forward's forecast of prospects of pharmaceutical companies to enter massive health industry
Chapter 3: Analysis of transformation of China's drugstore chain into major health pharmacy
3.1 status quo of transformation of drugstore chain into major health pharmacy
3.1.1 overview of transformation of drugstore chain into major health pharmacy
3.1.2 inevitability of transformation of drugstore chain into major health pharmacy
3.1.3 analysis of transformed major health pharmacy
3.1.4 analysis of scale of major health products market of drugstore chain
3.1.5 profit changes of transformation of drugstore chain into major health pharmacy
3.1.6 product structure of transformation of drugstore chain into major health pharmacy
3.2 main models of transformation of drugstore chain into major health pharmacy
3.2.1 introduction of major health product model
3.2.2 introduction of major health service model
3.2.3 introduction of the "shop in shop" model
3.3 analysis of store display of transformation of drugstore chain into major health pharmacy
3.3.1 status quo of store display of major health products
3.3.2 research of effect of store display of major health products
3.3.3 association between display of major health products and performance
3.3.4 advice for best display solution of major health products
3.4 reference of experience of case of transformation of drugstore chain into major health pharmacy
3.4.1 reference of success experience of transformation of drugstore chain into major health pharmacy
3.4.2 reference of failed cases of transformation of drugstore chain into major health pharmacy
(1) Shenxin Century Health New Concept Pharmacy
(2) Yangpu Store of Shanghai Kaixinren Pharmacy
(3) Hangzhou Jiuzhou Pharmacy Store
(4) Wuxi Yanshoutang Pharmacy
(5) Wuxi Mingda Pharmacy
3.5 ideas on transformation of drugstore chain into major health pharmacy and forecast
3.5.1 analysis of ideas on transformation of drugstore chain into major health pharmacy
3.5.2 Forward's forecast of transformation of drugstore chain into major health pharmacy
Chapter 4: Investment potential of subdivided markets of China's massive health industry
4.1 analysis of investment potential of toiletries market
4.1.1 status quo of development of toiletries market
(1) scale of toiletries market
(2) earnings of toiletries market
(3) competitive landscape of toiletries market
(4) risks of investment of toiletries market
4.1.2 overview of development of major health toiletries
4.1.3 scale of major health toiletries market
4.1.4 earnings of major health toiletries
4.1.5 investment potential of subdivided products of major health toiletries
(1) investment potential of shampoo
(2) investment potential of shower gel
(3) investment potential of hand sanitizer
(4) investment potential of soap
4.1.6 forecast of development of major health toiletries
4.2 analysis of investment potential of daily chemical products market
4.2.1 status quo of development of daily chemical products market
(1) scale of daily chemical products market
(2) earnings of daily chemical products market
(3) competitive landscape of daily chemical products market
(4) risks of investment of daily chemical products market
4.2.2 overview of development of major health daily chemical products
4.2.3 scale of major health daily chemical products market
4.2.4 earnings of major health daily chemical products
4.2.5 investment potential of subdivided products of major health daily chemical products
(1) investment potential of cosmetics
(2) investment potential of detergent
(3) investment potential of dental supplies
(4) investment potential of other cosmetic products
4.2.6 forecast of development of major health daily chemical products
4.3 analysis of investment potential of cosmeceutical products market
4.3.1 status quo of development of cosmeceutical products market
(1) scale of cosmeceutical products market
(2) earnings of cosmeceutical products market
(3) competitive landscape of cosmeceutical products market
(4) risks of investment of cosmeceutical products market
4.3.2 overview of development of major health cosmeceutical products
4.3.3 scale of major health cosmeceutical products market
4.3.4 earnings of major health cosmeceutical products
4.3.5 investment potential of subdivided products of major health cosmeceutical products
(1) investment potential of moisturizing makeup drugs
(2) investment potential of cream makeup drugs
(3) investment potential of whitening makeup drugs
(4) investment potential of anti-aging cosmeceuticals
(5) investment potential of acne makeup drugs
(6) investment potential of exfoliating cosmeceuticals
(7) investment potential of other cosmeceuticals
4.3.6 forecast of development of major health cosmeceutical products
4.4 analysis of investment potential of health products market
4.4.1 overview of development of health products
4.4.2 scale of health products market
4.4.3 earnings of health products market
4.4.4 competitive landscape of health products market
4.4.5 risks of investment of health products market
4.4.6 investment potential of subdivided products of health products
(1) investment potential of health products strengthening the immune system
(2) investment potential of health products relieving fatigue
(3) investment potential of health products improving sleepiness
(4) investment potential of health products of nutritional supplements
(5) investment potential of health products of beauty
(6) investment potential of health products of weight losing
(7) investment potential of health products of lowering blood lipid
(8) investment potential of health products of lowering blood glucose
4.4.7 forecast of development prospects of health products
4.5 analysis of investment potential of herbal tea market
4.5.1 overview of development of herbal tea
4.5.2 scale of herbal tea market
4.5.3 earnings of herbal tea market
4.5.4 competitive landscape of herbal tea market
4.5.5 risks of investment of herbal tea market
4.5.6 investment potential of of herbal tea products
4.5.7 forecast of development prospects of of herbal tea
4.6 analysis of investment potential of health equipment market
4.6.1 overview of development of health equipment
4.6.2 scale of health equipment market
4.6.3 earnings of health equipment market
4.6.4 competitive landscape of health equipment market
4.6.5 risks of investment of health equipment market
4.6.6 investment potential of subdivided products of health equipment
(1) investment potential of health equipment of massage
(2) investment potential of health equipment of body fitness
(3) investment potential of health equipment of treatment
(4) investment potential of health equipment of other functions
4.6.7 forecast of development prospects of health equipment
Chapter 5: Reference of development experience of foreign massive health industry
5.1 overview of development of the global massive health industry
5.1.1 analysis of development course of the global massive health industry
5.1.2 analysis of status quo of development of the global massive health industry
5.1.3 analysis of overall scale of the global massive health industry
5.1.4 analysis of product structure of the global massive health industry
5.1.5 analysis of subdivided markets of the global massive health industry
5.2 reference of development experience of massive health industry in developed countries
5.2.1 reference of development experience of massive health industry in America
5.2.2 reference of development experience of massive health industry in Japan
5.2.3 reference of development experience of massive health industry in South Korea
5.2.4 reference of development experience of massive health industry in Britain
5.2.5 reference of development experience of massive health industry in France
5.2.6 reference of development experience of massive health industry in Germany
5.3 reference of experience of leading multinationals into massive health
5.3.1 Abbott
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) analysis of operation of the company's massive health products
(4) reference of experience of the company's massive health strategy
(5) analysis of the company's investment in China
5.3.2 Johnson&Johnson
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) analysis of operation of the company's massive health products
(4) reference of experience of the company's massive health strategy
(5) analysis of the company's investment in China
5.3.3 Novartis AG
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) analysis of operation of the company's massive health products
(4) reference of experience of the company's massive health strategy
(5) analysis of the company's investment in China
5.3.4 Glaxo Smith Kline
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) analysis of operation of the company's massive health products
(4) reference of experience of the company's massive health strategy
(5) analysis of the company's investment in China
5.3.5 Sanofi-Aventis
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) analysis of operation of the company's massive health products
(4) reference of experience of the company's massive health strategy
(5) analysis of the company's investment in China
Chapter 6: Analysis of operation of leading enterprises of China's massive health industry
6.1 analysis of operation of pharmaceutical companies to enter massive health
6.1.1 Tasly Pharmaceutical Group Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.1.2 Yunnan Baiyao Group Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of the company's major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.1.3 Beijing Tongrentang Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.1.4 Mayinglong Pharmaceutical Group Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of the company's major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.1.5 Guangzhou Pharmaceutical Company Limited
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of the company's latest development trend
6.1.6 Xiuzheng Pharmaceutical Group
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of the company's capabilities of production and marketing
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of the company's latest development trend
6.1.7 Henan Wanxi Pharmaceutical Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of the company's capabilities of production and marketing
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of the company's latest development trend
6.1.8 Sanjing Pharmaceutical Co., Ltd. of Harbin Pharmaceutical Group
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
6.1.9 Kunming Dihon Pharmaceutical Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of the company's capabilities of production and marketing
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of the company's latest development trend
6.1.10 Zhejiang CONBA Pharmaceutical Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of the company's major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.1.11 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
6.1.12 Kangmei Pharmaceutical Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of the company's major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
6.1.13 Guizhou Yibai Pharmaceutical Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
6.1.14 Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.1.15 Henan Taloph Pharmaceutical Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's massive health products
1) analysis of the company's product structure
2) analysis of the company's massive health products
(4) analysis of the company's massive health market
(5) analysis of the company's massive health strategy
(6) analysis of advantages and disadvantages of the company's massive health strategy
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.2 analysis of process of massive health of drugstore chain benchmarking enterprises
6.2.1 Yunnan Hongxiang Yixintang Pharmaceutical ( Group ) Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) the company's suppliers and procurement
(4) analysis of the company's market expansion
(5) quantity and distribution of the company's stores
(6) the company's positioning and service object
(7) analysis of development of the company's massive health strategy
(8) analysis of advantages and disadvantages of the company's massive health strategy
(9) analysis of the company's latest development trend
6.2.2 China Nepstar Chain Drugstore Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) the company's suppliers and procurement
(4) analysis of the company's market expansion
(5) quantity and distribution of the company's stores
(6) the company's positioning and service object
(7) analysis of progress of the company's massive health
(8) analysis of the company's latest development trend
6.2.3 LBX Pharmacy Chain Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) the company's suppliers and procurement
(4) analysis of the company's market expansion
(5) quantity and distribution of the company's stores
(6) the company's positioning and service object
(7) analysis of progress of the company's massive health
(8) analysis of the company's latest development trend
6.2.4 Sinopharm National Pharmacy Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) the company's suppliers and procurement
(4) analysis of the company's market expansion
(5) quantity and distribution of the company's stores
(6) the company's positioning and service object
(7) analysis of progress of the company's massive health
(8) analysis of the company's latest development trend
6.2.5 Guangdong Dashenling Drugstore Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
(3) the company's suppliers and procurement
(4) analysis of the company's market expansion
(5) quantity and distribution of the company's stores
(6) the company's positioning and service object
(7) analysis of progress of the company's massive health
(8) analysis of the company's latest development trend
6.3 analysis of operation of benchmarking enterprises of health products
6.3.1 Amway ( China) Co. Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's product structure
(4) distribution of the company's regional markets
(5) analysis of the company's operation strategy
(6) analysis of advantages and disadvantages of the company's operation
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.3.2 Red Bull Vitamin Drink Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's product structure
(4) distribution of the company's regional markets
(5) analysis of the company's operation strategy
(6) analysis of advantages and disadvantages of the company's operation
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.3.3 Joincare Pharmaceutical Group Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's product structure
(4) distribution of the company's regional markets
(5) analysis of the company's operation strategy
(6) analysis of advantages and disadvantages of the company's operation
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.3.4 New Era Health Industry ( Group ) Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's product structure
(4) distribution of the company's regional markets
(5) analysis of the company's operation strategy
(6) analysis of advantages and disadvantages of the company's operation
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
6.3.5 Perfect ( China ) Co., Ltd.
(1) brief introduction of the company's development
(2) analysis of the company's operation
1) analysis of major economic indicators
2) analysis of the company's profitability capability
3) analysis of the company's operation capability
4) analysis of the company's solvency capability
5) analysis of the company's development capability
(3) analysis of the company's product structure
(4) distribution of the company's regional markets
(5) analysis of the company's operation strategy
(6) analysis of advantages and disadvantages of the company's operation
(7) analysis of investment, merger and restructuring of the company
(8) analysis of the company's latest development trend
Chapter 7: Advice for investment of China's massive health industry
7.1 analysis of development opportunity of massive health industry
7.1.1 analysis of development prospects of massive health industry
7.1.2 analysis of advantages of pharmaceutical companies to enter massive health
7.1.3 analysis of advantages of pharmaceutical companies to enter massive health
7.2 analysis of risks into massive health industry
7.2.1 analysis of risk of product structure
7.2.2 analysis of risk of market changes
7.2.3 analysis of risk of own operation
7.2.4 analysis of risk of product homogeneity
7.3 essential qualities into massive health industry
7.3.1 essential qualities for large pharmaceutical companies to develop massive health
7.3.2 essential qualities for pharmacies to develop massive health
7.4 advice for investment of China's massive health industry
7.4.1 advice for pharmaceutical companies to enter massive health
7.4.2 advice for pharmacies to transform to massive health
The terminal is in urgent need of innovative formats; while at the same time, consumers need a platform that can provide health services and health care; therefore, pharmacies' major health strategy emerges.
In recent years, China's research and development costs of drugs are increasing while the difficulty of drug development and market cycle are expanding. In the large environment of rapidly rising costs of raw materials especially traditional Chinese medicine, the pharmaceutical industry suffers from essential drug system, bidding and management of drug prices and other factors. Competition of prescription drugs is increasing. Pharmaceutical companies extend to "massive health" domain, develop new business and expand new markets, which becomes imminent of the transformation of economic development mode and to seek new growth points.
At the same time, for the pharmacy, the pure drug profits fell seriously. "Parity" gradually comes to an end. The terminal is in urgent need of innovative formats; while at the same time, consumers need a platform that can provide health services and health care; therefore, pharmacies' major health strategy emerges. Laying some of the high-margin product varieties in pharmacies is suitable for terminal appetite. Massive health strategy has market demands and the potential to be tapped. However, very few companies succeed in the current major health market.
This report analyzes massive health of the domestic pharmaceutical companies, pharmacies; investment potential of subdivided markets of massive health; combining a large number of domestic and foreign "massive health" cases, analyzes the reasons for their success or failure; summarizes a truly effective "massive health" road, to help enterprises avoid detours, wrong ways in the transformation and upgrading. It helps enterprises preparing to enter massive health achieve big successes and achieve a qualitative leap in the development of enterprises.
This report is based on professional tracking and research by Forward Intelligence on massive health industry. It uses scientific analysis models and analyses comprehensively and accurately the structure system from the overall height of the industry for you.
This report is based on various aspects of the macroeconomic environment of the industry like economy, policy, and society and does comprehensive and in-depth analysis of the current development status, typical cases and prospects of massive health strategy. It describes the development of massive health strategy in different pharmaceutical companies, pharmaceutical companies and enterprises of other natures. It also describes development experience of the leading international and domestic companies.
Meanwhile, based on first-hand market data of the whole industry in the past five years, it can allow you to fully and accurately understand main points and key points of implementation of massive health strategy in enterprises.
The greatest feature of this report is forward-looking, timeliness and practicality. This report is a rare quality for drug manufacturing enterprises, pharmacies and other medical institutions, medical / health institutions and investment companies to accurately understand the latest developments of the industry, grasp market opportunities, make the right business decisions and clear corporate directions. It is also the industry's first on comprehensive and systematic analysis of massive health strategy and typical cases.
This report will help drug manufacturing enterprises, pharmacies and other medical institutions, health care products manufacturers accurately understand the latest developments of the industry and early detect blank points of industry market, opportunities, growth and profitability points ...... it will help prospectively grasp unmet market needs and trends of the industry and become a good advantage for sustainable development, effectively avoid the investment risks from the industry, more efficiently consolidate or expand appropriate strategic target markets, and firmly grasp the initiative authority in market competition.
The National Bureau of Statistics Foreign-related investigation Permission
National Innovation Company and Dual Software Certified Enterprise
The only DRC desginated Enterprise of the Industry Yearbook
National Ministry of Commerce designated Industrial Early Warning and Monitoring Workstation
Guangdong Province Enterprise of Observing Contract and Valuing Credit
Qianzhan is an industry consulting service provider with national innovation company qualification, independent research and development of industrial big data and Dual Software Certification.
Qianzhan is a consulting and research organization that has been engaged in business consulting for over 16 years in China.
Qianzhan is a consulting service provider with a team of nearly 300 industrial researchers and analysts.
Qianzhan is a consulting service provider with an in-house expert pool of 1200 experts.
Qianzhan is a research and consulting organization that have served 180000 clients and received over positive comments from 100000 of our clients.
Qianzhan is an industry research and consulting organization that has been designated by the highest authority, the DRC, to prepare the yearbook.
Qianzhan is an industry planning and consulting organization that adopts the internationally synchronized SCP scientific analysis model and the perfect industry chain research map to guide the business planning and consulting.
Qizhan is a consulting service organization that helps enterprises to solve the five aspects of industry research, planning, strategic design, capital operation and implementation.
Free Hotline：+86 400-068-7188
Customer Hotline：+86 755 - 82925195 / 82925295
Email Address：service@qianzhan.com
3rd Floor, FIYTA Building West, High Tech South Avenue 1, Nanshan District, Shenzhen, China
Location：Rm.1106, Building 1, Jiayu International Plaza, Songhu Road, Yangpu District,
Shanghai, China
Quality Assured
Offer a forward-looking vision to all of our customers.
Customer Service
We welcome any feedbacks and suggestions to make our customers 100% satisfied.
Qualification Certificates
Having more than 20 qualification certificates, including Innovation Company Certificate and Foreign-related investigation Permission etc.
Customers Testimonials
Thank you for recognizing our high quality products and professional, rigorous and sincere service.
